Biogen Idec (BIIB) Tops Q3 EPS by 31c; Boosts FY14 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Oil slips as Saudi Arabia offers more crude via Oman
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
RBC Capital Comments on Biogen (BIIB) and Tecfidera PML Case; Analyst Maintains Outperform Rating
October 22, 2014 1:27 PM EDTRBC Capital maintained an Outperform rating on Biogen (NASDAQ: BIIB) with a price target of $375. Analyst Michael J. Yee commented on today's decline, linking it to light Tecfidera results. He also tied the fall in part to the disclosure of a PML case for Tecfidera. After 4.5 years of... More
Baird Upgrades Biogen (BIIB) to Outperform
October 22, 2014 12:45 PM EDTBaird upgraded Biogen (NASDAQ: BIIB) from Neutral to Outperform with a price target of $382.00.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $326.77 yesterday.
... MoreBiogen (BIIB): Deutsche Bank Comments on Recent Weakness And Compares it to Celgene (CELG)
October 22, 2014 10:52 AM EDTDeutsche Bank maintained a Buy rating on Biogen (NASDAQ: BIIB) with a price target of $430. Analyst Robyn Karnauskas commented on recent weakness and compared the stock to Celgene (NASDAQ: CELG). Overall, she is positive on both stocks.
"Biogen is trading weak post earnings due to 1) slower sequential revenue growth and 2) One PML case with Tecfidera disclosed on todays call. While we note that there is a good risk/reward... More
